Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of aBRCA1orBRCA2Mutation
Top Cited Papers
- 26 July 2001
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 345 (4), 235-240
- https://doi.org/10.1056/nejm200107263450401
Abstract
Multiparity and the use of oral contraceptives reduce the risk of ovarian cancer, but their effects on this risk in women with a BRCA1 or BRCA2 mutation are unclear.Keywords
This publication has 22 references indexed in Scilit:
- Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US WomenJAMA, 2001
- Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidenceClinical Endocrinology, 1998
- Cancer Incidence in a Cohort of Infertile WomanAmerican Journal of Epidemiology, 1998
- Ovarian cancer, ovulation and side of originBritish Journal of Cancer, 1995
- Parity, age at first childbirth, and risk of ovarian cancerThe Lancet, 1994
- Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancerJournal of Clinical Epidemiology, 1990
- Risk factors for ovarian cancer: a case-control studyBritish Journal of Cancer, 1989
- A case-control study of epithelial ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1989
- PERSONAL AND ENVIRONMENTAL CHARACTERISTICS RELATED TO EPITHELIAL OVARIAN CANCERAmerican Journal of Epidemiology, 1988
- MEASURING THE SEPARATE EFFECTS OF LOW PARITY AND ITS ANTECEDENTS ON THE INCIDENCE OF OVARIAN CANCERAmerican Journal of Epidemiology, 1988